22 Mar MVI Expands Clinical Trial
Madison Vaccines Incorporated’s clinical trial for metastatic prostate cancer is expanding to the University of Washington, its third site, the company announced recently. According to a release, MVI-118 is being explored for use in combination with androgen deprivation therapy to delay resistance and prolong duration of disease control...